Dataciencia

Colección SciELO Chile

Psychopharmacological Interventions

Indexado

Scopus

SCOPUS_ID:84885387107

DOI

10.1002/9781119941101.CH9

Año

2012

Tipo

Citas Totales

Autores Afiliación Chile

Instituciones Chile

% Participación
Internacional

Autores
Afiliación Extranjera

Instituciones
Extranjeras

Métricas Externas

PlumX	Altmetric	Dimensions

Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:

Plumx: https://plumanalytics.com/learn/about-metrics/
Altmetric: https://www.altmetric.com/about-altmetrics/what-are-altmetrics/
Dimensions: https://www.dimensions.ai/why-dimensions/

Disciplinas de Investigación

WOS
Sin Disciplinas

Scopus
Sin Disciplinas

SciELO
Sin Disciplinas

Muestra la distribución de disciplinas para esta publicación.

Publicaciones WoS (Ediciones: ISSHP, ISTP, AHCI, SSCI, SCI), Scopus, SciELO Chile.

Colaboración Institucional

Muestra la distribución de colaboración, tanto nacional como extranjera, generada en esta publicación.

Autores - Afiliación

Ord.	Autor	Género	Institución - País
1	Thekdi, Seema M.	Mujer	University of Texas MD Anderson Cancer Center - Estados Unidos
2	Irarráazaval, María Elisa	Mujer	Fundación Arturo López Pérez - Chile
3	Dunn, Laura B.	Mujer	University of California, San Francisco - Estados Unidos

Muestra la afiliación y género (detectado) para los co-autores de la publicación.

Financiamiento

Fuente
Novartis
National Institute of Mental Health
National Institute of Child Health and Human Development
Shire
Janssen Pharmaceuticals
Otsuka

Muestra la fuente de financiamiento declarada en la publicación.

Agradecimientos

Agradecimiento
Dr. Thomas Spencer receives research support from, is a speaker for, or is on the Advisory Board of the following sources: Shire, Eli Lilly and Company, GlaxoSmithKline, Ortho-McNeil, Inc., Novartis, New River Pharmaceuticals, Cephalon, Pfizer, and the National Institute of Mental Health (NIMH). Dr. Joseph Biederman is currently receiving research support from the following sources: Bristol-Myers Squibb, Eli Lilly and Company, Janssen, L.P., Ortho-McNeil, Inc., Otsuka, Shire, NIMH, and the National Institute of Child Health and Human Development Dr. Joseph Biederman is currently a consultant/advisory board member for the following pharmaceutical companies: Janssen, L.P., Ortho-McNeil, Inc., Novartis, and Shire. Dr. Joseph Biederman is currently a speaker for the following speaker's bureaus: Janssen, Ortho-McNeil, Inc., Novartis, Shire, and UCB Pharma, Inc. In previous years, Dr. Joseph Biederman received research support, consultation fees, or speaker's fees for/from the following additional sources: Abbott, AstraZeneca, Celltech, Cephalon, Eli Lilly and Company, Esai, Forest, GlaxoSmithKline, Gliatech Inc., NARSAD, New River Behavioral HealthCare, the National Institute on Drug Abuse, Novartis, Noven, Neurosearch, Pfizer, Pharmacia, The Prechter Foundation, The Stanley Foundation, and Wyeth.

Agradecimiento

Dr. Thomas Spencer receives research support from, is a speaker for, or is on the Advisory Board of the following sources: Shire, Eli Lilly and Company, GlaxoSmithKline, Ortho-McNeil, Inc., Novartis, New River Pharmaceuticals, Cephalon, Pfizer, and the National Institute of Mental Health (NIMH). Dr. Joseph Biederman is currently receiving research support from the following sources: Bristol-Myers Squibb, Eli Lilly and Company, Janssen, L.P., Ortho-McNeil, Inc., Otsuka, Shire, NIMH, and the National Institute of Child Health and Human Development Dr. Joseph Biederman is currently a consultant/advisory board member for the following pharmaceutical companies: Janssen, L.P., Ortho-McNeil, Inc., Novartis, and Shire. Dr. Joseph Biederman is currently a speaker for the following speaker's bureaus: Janssen, Ortho-McNeil, Inc., Novartis, Shire, and UCB Pharma, Inc. In previous years, Dr. Joseph Biederman received research support, consultation fees, or speaker's fees for/from the following additional sources: Abbott, AstraZeneca, Celltech, Cephalon, Eli Lilly and Company, Esai, Forest, GlaxoSmithKline, Gliatech Inc., NARSAD, New River Behavioral HealthCare, the National Institute on Drug Abuse, Novartis, Noven, Neurosearch, Pfizer, Pharmacia, The Prechter Foundation, The Stanley Foundation, and Wyeth.